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Morphine is the recommended and most widely used strong
opioid analgesic for chronic cancer pain (WHO, 1986). Des-
pite its widespread and long-standing use, however, there is
only limited knowledge of its pharmacokinetics. This is an
important gap because such knowledge may shed light on
certain aspects of the use of morphine and may also be
helpful in some difficult clinical situations.
A unique feature of morphine in the treatment of cancer
pain is that a very wide range of doses may be required and
the needs of any individual may vary from only 30 mg a day
to several grams a day, a dose differential of several hundred-
fold to achieve the same clinical endpoint. There are also
wide variations in idiosyncratic responses to the drug, both in
terms of tolerance during chronic use, and intolerance. Toler-
ance refers to the situation in which increasing doses of a
drug are required to achieve the same effect. This may be due
to pharmacokinetic effects such as enzyme induction or in-
creased excretion, or adaptive changes in receptor numbers
or sensitivity.
Tolerance to the analgesic effects of morphine in chronic
use does not occur as frequently as one would predict from
animal models, and the explanation for this is not clear. The
phenomenon of 'selective tolerance' is also difficult to ex-
plain: the fact that patients usually develop tolerance to the
sedative and/or emetogenic effects ofmorphine within a short
while of starting chronic administration whereas the analgesic
effect continues, and patients' dose requirements may remain
stable for long periods of time.
A very small proportion of patients are unable to take
morphine because of excessive drowsiness, hallucinations,
dysphoria, or intractable nausea and vomiting. Again either
pharmacokinetic variations or idiosyncratic differences in
opioid sensitivity may be implicated.
Not all pain in cancer responds to morphine and it is
possible that in some cases this lack of response may have a
pharmacokinetic explanation. On the other hand some types
of pain, particularly neuropathic or neuralgic pain, appear to
be inherently opioid-insensitive. In these situations it would
be of value to distinguish inadequate pain control due to
altered morphine kinetics from true opioid resistance in order
to initiate appropriate changes in therapy.
Thus knowledge of the pharmacokinetics of morphine has
important clinical implications. Progress in this field has been
hampered by the difficulty in producing sensitive and specific
assay methods for the measurement of morphine in body
fluids. Recently specific radio-immunoassays and high per-
formance liquid chromatography have allowed more reliable
measurements of its pharmacokinetic parameters.
Absorption of morphine after oral administration occurs
predominantly in the alkaline medium of the upper small
bowel (morphine is a weak base) and is almost complete.
Morphine is also well absorbed across the rectal mucosa
(Hanning et al., 1988).
Absorption by the buccal route appears efficient for oral
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solutions of morphine (Al Sayed et al., 1987) but experience
with tablet formulations has demonstrated poor and unreli-
able absorption by this route (Fisher et al., 1987; Hoskin et
al., 1989a). Similarly, absorption of inhaled morphine
appears unsatisfactory (Chrubasik et al., 1987).
After oral administration, extensive presystemic elimina-
tion of the drug occurs during its passage across the small
bowel wall and through the liver. About 90% is converted
into metabolites, principally the glucuronide conjugates
morphine-3-glucuronide (M3G) and morphine-6-glucuronide
(M6G), and minor metabolites including codeine, nor-
morphine and morphine ethereal sulphate. In man the liver
appears to be the predominant site for metabolism, although
in animal models extrahepatic metabolism has been demon-
strated in the small bowel of rodents (Dahlstrom & Paalzow,
1978) and the proximal renal tubule (Schali & Roch-Ramel,
1982). These sites may become important where liver func-
tion is impaired, although a recent study of morphine
pharmacokinetics during the anhepatic phase in liver trans-
plant patients found only very low levels of M3G and M6G
prior to recovery of liver function (Bodenham et al., 1989).
An area of particular importance which has emerged in
recent years is the possible role of the metabolites of mor-
phine in the pharmacodynamic effects of the drug. Several of
the metabolites have been demonstrated in animal models to
have analgesic activity, in particular M6G (Shimomura et al.,
1971), normorphine (Lasagna & de Kornfeld, 1958), codeine
and morphine ethereal sulphate. In contrast M3G, which is
the major metabolite of morphine, is inactive (Shimomura et
al., 1971). M6G in rodents has analgesic activity 20-45 times
greater than morphine when injected directly into the central
nervous system (Shimomura et al., 1971; Pasternak et al.,
1987).
The ratio of the areas under the serum concentration
versus time curves (AUC) for morphine and M6G after oral
administration in man is of the order of 1:10. The presence
of high concentrations of this substance with strong analgesic
properties after oral administration of morphine is thought
to account for a significant part of the analgesic effect seen
from the parent drug (Hanks et al., 1987). This would account
for a number of clinical observations, in particular that single
oral doses appear to give poor analgesia while repeated doses
are highly effective, and that under conditions in which M6G
accumulates, in particular renal failure, increased sensitivity
to morphine and clinical toxicity may be observed.
Both morphine and M6G are widely distributed within the
body. In a group of healthy volunteers the volume of distri-
bution for morphine was found to be 5.31 kg-', and for
M6G 3.61 kg-', although there was enormous individual
variation (Hoskin et al., 1989a). Both morphine and M6G
have been detected in CSF (Hoskin et al., 1989b) but practi-
cal difficulties in obtaining serial samples of CSF in human
subjects has made accurate estimation of their relative con-
centrations difficult to achieve. Recent data, however, from
two patients with indwelling intrathecal catheters who receiv-
ed a single oral dose of morphine, have demonstrated a ratio
of AUCs for morphine to M6G in CSF of 1:6 and 1:2.4
respectively (compared with 1:9 and 1:11 in plasma) (Poulain
et al., 1990). This supports the hypothesis that significant
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quantities of M6G enter the CSF after oral administration
and that this substance is therefore likely to make a major
contribution towards the resulting analgesic effects, mediated
through opioid receptors in the central nervous system.
Excretion of morphine occurs predominantly in the urine
in the form of morphine glucuronides with unchanged mor-
phine representing between 2 and 10% of the total, inde-
pendent of dose. Some 70-80% of an administered dose is
excreted within 48 h of administration and most of this
appears within the first 24 h (Berkowitz, 1976). An important
consequence of this is that in renal failure, whilst morphine
clearance is essentially unchanged, extensive accumulation of
morphine glucuronides has been demonstrated (Aitkenhead
et al., 1984; Woolner et al., 1986; Sawe & Odar Cedarlof,
1987). It seems likely that M6G accounts for the observed
sensitivity to morphine and development of morphine toxi-
city in patients with renal impairment (Osborne et al., 1986)
although other active metabolites may also contribute in this
situation (Glare et al., 1990).
Morphine can be detected in faeces after non-oral admini-
stration and there is increasing evidence that the entero-
hepatic circulation of morphine demonstrated in animal
models also occurs in man. Significant amounts of M3G and
M6G can be detected in bile following oral administration
(Hanks et al., 1988) and their hydrolysis and reabsorption of
morphine may account for the presence of second peaks on
the profile of serum concentrations versus time after oral
administration (Leslie et al., 1980; Poulain et al., 1988).
Our understanding of the pharmacokinetics of morphine is
expanding but there remains a gulf between this and the
pharmacodynamics of the drug. No clear correlation has
been demonstrated between plasma concentrations of mor-
phine and its pharmacological action. This may in part reflect
limitations in the accuracy of measuring morphine in early
studies and it is also important to consider that plasma
concentrations are a poor reflection of concentrations within
the central nervous system which will be the important deter-
minants of major clinical effects such as analgesia. Attempts
to use pharmacodynamic models suggest that a relationship
may be demonstrated between analgesia and concentrations
in a third effector compartment (Kaiko et al., 1978). M6G
concentrations appear to mirror those of morphine in
plasma, reaching a peak soon after peak morphine concen-
trations. Attempts to model morphine and M6G concentra-
tions with measured pharmacodynamic effects have so far
failed to distinguish an effect of the metabolite from that of
the parent drug (Hoskin, 1990).
Clinical use of morphine remains, therefore, essentially
empirical. The most important factor determining the dose
required by an individual is the severity of pain. A retrospec-
tive analysis of clinical data from cancer patients indicates
that age is also a predictor of dose: patients under 60 years
had a median maximum (4-hourly) dose requirement of
55 mg compared with only 25-30 mg for those over 60 years
(Hoskin & Hanks, 1988). Pharmacokinetic differences for
morphine in different age groups have been demonstrated
with a reduced clearance and smaller volume of distribution
in elderly patients (Kaiko, 1980; Owen et al., 1983). Other
potential dose-modifying parameters such as impaired hepa-
tic and renal function failed in the retrospective study men-
tioned above to show a significant relationship to dose,
although pharmacokinetic data from non-cancer patients has
demonstrated impaired clearance of morphine in advanced
hepatic failure (Mazoit et al., 1987) and accumulation of
active metabolites in renal failure as mentioned earlier.
Similarly, factors influencing enterohepatic circulation of
morphine, such as cholestasis, bowel resection and the use of
antibiotics, have yet to be shown to have a major impact on
the overall dose requirements.
There are no data at present which would allow an ex-
planation for idiosyncratic intolerance of morphine on the
basis of pharmacokinetic behaviour. Enormous variation
occurs and it is possible that sensitivity to morphine may be
related to individual patterns of absorption, altered distribu-
tion of morphine and its active metabolite or metabolites, the
production of different amounts and patterns of active meta-
bolites, or prolonged excretion of either morphine or its
metabolites. Other simpler and more direct effects of mor-
phine have been proposed. For example, it has been suggest-
ed that nausea and vomiting may be largely attributable in
some patients to the local effects of morphine on the bowel,
resulting in a functional pyloric stenosis (Twycross & Lack,
1986).
The aim of continuing and future research into the phar-
macokinetics of morphine must be to increase the under-
standing of the relationship between drug handling and the
clinical effects observed, thereby enabling more rational and
effective use of this analgesic. The current focus of attention
on the role of active metabolites demands that alongside
clinical studies there is continued development of the assay
technology required to detect the nanomolar quantities which
are present after oral administration of clinically relevant
doses. In addition, the work of the pharmaceutical industry
in developing more palatable forms of morphine and conven-
ient controlled release preparations will ensure that the
patient with advanced cancer is enabled to receive adequate
and effective pain control with a minimum of inconvenience.
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